Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 121, Issue 2, 2011, Pages 303-308

  Farley, John ^a   Sill, Michael W ^b,c   Birrer, Michael ^d   Walker, Joan ^e   Schilder, Russell J ^f   Thigpen, J Tate ^g   Coleman, Robert L ^h   Miller, Brigitte E ⁱ   Rose, Peter G ^j   Lankes, Heather A ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

Cervical cancer; Cetuximab; Cisplatin

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CETUXIMAB; CISPLATIN; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UROGENITAL TRACT DISEASE; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 79955481029     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.01.030     Document Type: Article

References (46)

1. H.M. Keys, B.N. Bundy, F.B. Stehman, L.I. Muderspach, W.E. Chafe, and C.L. Suggs III Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage 1B cervical carcinoma N Engl J Med 340 1999 1154 1161 (Pubitemid 29177874)
2. M. Morris, P.J. Eifel, J. Lu, P.W. Grigsby, C. Levenback, and R.E. Stevens Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N Engl J Med 340 1999 1137 1143 (Pubitemid 29177872)
3. P.G. Rose, B.N. Bundy, E.B. Watkins, J.T. Thigpen, G. Deppe, and M.A. Maiman Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 341 1999 1144 1153 (Pubitemid 29177873)
4. F.B. Stehman, S. Ali, H.M. Keys, L.I. Muderspach, W.E. Chafe, and D.G. Gallup Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Am J Obstet Gynecol 197 503 2007 e1 e6
5. H.E. Averette, R.C. Dudan, and J.H. Ford Jr. Exploratory celiotomy for surgical staging of cervical cancer Am J Obstet Gynecol 113 1972 1090 1096
6. M.L. Berman, H. Keys, W. Creasman, P. DiSaia, B. Bundy, and J. Blessing Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study) Gynecol Oncol 19 1984 8 16 (Pubitemid 14027471)
7. P. Lepanto, P. Littman, J. Mikuta, L. Davis, and J. Celebre Treatment of para-aortic nodes in carcinoma of the cervix Cancer 35 1975 1510 1513
8. J.H. Nelson Jr., J. Boyce, M. Macasaet, T. Lu, J.F. Bohorquez, and A.D. Nicastri Incidence, significance and follow-up of para-aortic lymph node metastases in late invasive carcinoma of the cervix Am J Obstet Gynecol 128 1977 336 340 (Pubitemid 8128942)
9. A. Sudarsanam, K. Charyulu, J. Belinson, H. Averette, M. Goldberg, and B. Hintz Influence of exploratory celiotomy on the management of carcinoma of the cervix. A preliminary report Cancer 41 1978 1049 1053 (Pubitemid 8313245)
10. T. Akimoto, N.R. Hunter, L. Buchmiller, K. Mason, K.K. Ang, and L. Milas Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas Clin Cancer Res 5 1999 2884 2890 (Pubitemid 29493967)
11. S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174 (Pubitemid 30399181)
12. L. Milas, K. Mason, N. Hunter, S. Petersen, M. Yamakawa, and K. Ang In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708 (Pubitemid 30111496)
13. C. Bianco, R. Bianco, G. Tortora, V. Damiano, P. Guerrieri, and P. Montemaggi Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type 1 protein kinase A antisense oligonucleotide Clin Cancer Res 6 2000 4343 4350
14. F. Ciardiello, R. Bianco, V. Damiano, S. De Lorenzo, S. Pepe, and S. De Placido Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 Clin Cancer Res 5 1999 909 916 (Pubitemid 29180844)
15. F. Robert, M.P. Ezekiel, S.A. Spencer, R.F. Meredith, J.A. Bonner, and M.B. Khazaeli Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 3234 3243 (Pubitemid 32591441)
16. A.M. Kersemaekers, G.J. Fleuren, G.G. Kenter, L.J. Van den Broek, S.M. Uljee, and J. Hermans Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis Clin Cancer Res 5 1999 577 586 (Pubitemid 29131967)
17. C.M. Lee, D.C. Shrieve, K.A. Zempolich, R.J. Lee, E. Hammond, and D.L. Handrahan Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix Gynecol Oncol 99 2005 15 21
18. D.K. Gaffney, D. Haslam, A. Tsodikov, E. Hammond, J. Seaman, and J. Holden Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy Int J Radiat Oncol Biol Phys 56 2003 922 928 (Pubitemid 36794022)
19. Y.T. Kim, S.W. Park, and J.W. Kim Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma Gynecol Oncol 87 2002 84 89 (Pubitemid 36027106)
20. N.J. Cho, Y.B. Kim, T.K. Park, G.E. Kim, K. Park, and K.J. Song P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma Gynecol Oncol 91 2003 346 353 (Pubitemid 37351026)
21. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
22. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1989 1 10 (Pubitemid 19099520)
23. H.J. Long III, B.N. Bundy, E.C. Grendys Jr., J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 2005 4626 4633 (Pubitemid 46224065)
24. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 2004 3113 3119 (Pubitemid 41103724)
25. B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 2009 4649 4655
26. W.B. London, and M.N. Chang One- and two-stage designs for stratified phase II clinical trials Stat Med 24 2005 2597 2611 (Pubitemid 41300797)
27. D. Pfeiffer, B. Stellwag, A. Pfeiffer, P. Borlinghaus, W. Meier, and P. Scheidel Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix Gynecol Oncol 33 1989 146 150 (Pubitemid 19112903)
28. Y. Hayashi, T. Hachisuga, T. Iwasaka, K. Fukuda, Y. Okuma, and M. Yokoyama Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement Gynecol Oncol 40 1991 147 151
29. R.J. Hale, C.H. Buckley, W.J. Gullick, H. Fox, J. Williams, and F.L. Wilcox Prognostic value of epidermal growth factor receptor expression in cervical carcinoma J Clin Pathol 46 1993 149 153 (Pubitemid 23076346)
30. G.B. Kristensen, R. Holm, V.M. Abeler, and C.G. Tropé Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study Cancer 78 1996 433 440 (Pubitemid 26250528)
31. G. Scambia, G. Ferrandina, M. Distefano, G. D'Agostino, P. Benedetti-Panici, and S. Mancuso Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer Cancer Lett 123 1998 135 139 (Pubitemid 28064090)
32. N. Silvestris, S. Tommasi, D. Santini, A. Russo, G. Simone, and D. Petriella KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue Expert Opin Biol Ther 9 2009 565 577
33. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
34. K.Y. Chung, J. Shia, N.E. Kemeny, M. Shah, G.K. Schwartz, and A. Tse Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810 (Pubitemid 46211358)
35. B. Burtness, M.A. Goldwasser, W. Flood, B. Mattar, and A.A. Forastiere Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 2005 8646 8654 (Pubitemid 46211507)
36. J. Slama, M. Drazdakova, P. Dundr, D. Fischerova, M. Zikan, and I. Pinkavova High-risk human papillomavirus DNA in the primary tumor, sentinel, and nonsentinel pelvic lymph nodes in patients with early-stage cervical cancer: a correlation with histopathology Int J Gynecol Cancer 19 2009 703 707
37. Human papillomavirus 16 and head and neck squamous cell carcinoma Int J Cancer 120 2007 2386 2392
38. E. Ringström, E. Peters, M. Hasegawa, M. Posner, M. Liu, and K.T. Kelsey Human papillomavirus type 16 and squamous cell carcinoma of the head and neck Clin Cancer Res 8 2002 3187 3192 (Pubitemid 35155029)
39. B. Kumar, K.G. Cordell, J.S. Lee, F.P. Worden, M.E. Prince, and H.H. Tran EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer J Clin Oncol 26 2008 3128 3137
40. G. Hu, W. Liu, J. Mendelsohn, L.M. Ellis, R. Radinsky, and M. Andreeff Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells J Natl Cancer Inst 89 1997 1271 1276 (Pubitemid 27371947)
41. S.H. Kim, Y.S. Juhnn, S. Kang, S.W. Park, M.W. Sung, and Y.J. Bang Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1, 2 and P13K/Akt Cell Mol Life Sci 63 2006 930 938 (Pubitemid 43724080)
42. T. Enomoto, M. Inoue, A.O. Perantoni, N. Terakawa, O. Tanizawa, and J.M. Rice K-ras activation in neoplasms of the human female reproductive tract Cancer Res 50 1990 6139 6145 (Pubitemid 20323664)
43. T. Enomoto, M. Inoue, A.O. Perantoni, G.S. Buzard, H. Miki, and O. Tanizawa K-ras activation in premalignant and malignant epithelial lesions of the human uterus Cancer Res 51 1991 5308 5314
44. F.R. Hirsch, M. Varella-Garcia, and R. Dziadziuszko Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer Clin Cancer Res 14 2008 6317 6323
45. F.R. Hirsch, R.S. Herbst, and C. Olsen Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy J Clin Oncol 26 2008 3351 3357
46. R.J. Schilder, M.W. Sill, Y.C. Lee, and R. Mannel A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study Int J Gynecol Cancer 19 2009 929 933